Parag V. Meswani
Corporate Officer/Principal bij ACADIA PHARMACEUTICALS INC.
Profiel
Parag V.
Meswani is currently the Senior Vice President-Trofinetide at ACADIA Pharmaceuticals, Inc. Prior to this, he held positions at Biogen, Inc. as the Chief Executive Officer-Commercial Operations, at Spark Therapeutics, Inc. as the Head-US Marketing, and at Sio Gene Therapies, Inc. as the Chief Commercial Officer.
Dr. Meswani has an MBA from The Trustees of Columbia University in The City of New York, an undergraduate and doctorate degree from Ernest Mario School of Pharmacy, and another MBA from Columbia Business School.
Actieve functies van Parag V. Meswani
| Bedrijven | Functie | Begin |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01-04-2022 |
Eerdere bekende functies van Parag V. Meswani
| Bedrijven | Functie | Einde |
|---|---|---|
| SIO GENE THERAPIES INC. | Operationeel Directeur | 06-10-2020 |
| BIOGEN INC. | Corporate Officer/Principal | - |
| SPARK THERAPEUTICS, INC. | Verkoop & Marketing | - |
Opleiding van Parag V. Meswani
| Ernest Mario School of Pharmacy | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
